PURPOSE: The aim of this study was to determine the prevalence and pattern of unlicensed and off-label drugs prescribed to hospitalized children at the Department of Paediatrics, University Hospital Rijeka, Croatia. METHODS: A prospective cross-sectional study was performed on 1 day each month during a 12 month period and included all hospitalized children and adolescents. RESULTS: A total of 1,643 prescriptions for 198 different drugs were prescribed to 531 out of 691 (77%) hospitalized patients. Forty-six percent of the different drugs were prescribed in an unlicensed or off-label manner. Of all drug prescriptions, 25% were either unlicensed or off-label. Forty-eight percent of the patients received either an unlicensed or off-label drug. The most frequently prescribed off-label drugs were proton pump inhibitors. CONCLUSION: Unlicensed and off-label drug use is common. It is not illegal and may be clinically appropriate but is associated with a number of clinical, safety, and ethical issues. Regulatory authorities should use existing clinical evidence on the use of off-label and unlicensed drugs in decision making. Marketing authorization holders and national regulatory authorities should monitor for any safety concerns associated with unlicensed and off-label drug use and take appropriate measures as well as identify research priorities and mandate clinical studies to resolve important questions.
PURPOSE: The aim of this study was to determine the prevalence and pattern of unlicensed and off-label drugs prescribed to hospitalized children at the Department of Paediatrics, University Hospital Rijeka, Croatia. METHODS: A prospective cross-sectional study was performed on 1 day each month during a 12 month period and included all hospitalized children and adolescents. RESULTS: A total of 1,643 prescriptions for 198 different drugs were prescribed to 531 out of 691 (77%) hospitalized patients. Forty-six percent of the different drugs were prescribed in an unlicensed or off-label manner. Of all drug prescriptions, 25% were either unlicensed or off-label. Forty-eight percent of the patients received either an unlicensed or off-label drug. The most frequently prescribed off-label drugs were proton pump inhibitors. CONCLUSION: Unlicensed and off-label drug use is common. It is not illegal and may be clinically appropriate but is associated with a number of clinical, safety, and ethical issues. Regulatory authorities should use existing clinical evidence on the use of off-label and unlicensed drugs in decision making. Marketing authorization holders and national regulatory authorities should monitor for any safety concerns associated with unlicensed and off-label drug use and take appropriate measures as well as identify research priorities and mandate clinical studies to resolve important questions.
Authors: Ermindo R Di Paolo; Hans Stoetter; Jacques Cotting; Peter Frey; Mario Gehri; Maja Beck-Popovic; Jean-François Tolsa; Sergio Fanconi; André Pannatier Journal: Swiss Med Wkly Date: 2006-04-01 Impact factor: 2.193
Authors: Madlen Gazarian; Maria Kelly; John R McPhee; Linda V Graudins; Robyn L Ward; Terence J Campbell Journal: Med J Aust Date: 2006-11-20 Impact factor: 7.738
Authors: G W 't Jong; P D van der Linden; E M Bakker; N van der Lely; I A Eland; B H C Stricker; J N van den Anker Journal: Eur J Clin Pharmacol Date: 2002-06-15 Impact factor: 2.953
Authors: Linda Hsien; André Breddemann; Anne-Kristina Frobel; Andreas Heusch; Klaus G Schmidt; Stephanie Läer Journal: Pharm World Sci Date: 2008-01-26
Authors: Giovanni Tafuri; Francesco Trotta; Hubert G M Leufkens; Nello Martini; Luciano Sagliocca; Giuseppe Traversa Journal: Eur J Clin Pharmacol Date: 2008-09-17 Impact factor: 2.953
Authors: H Christine Allen; M Connor Garbe; Julie Lees; Naila Aziz; Hala Chaaban; Jamie L Miller; Peter Johnson; Stephanie DeLeon Journal: J Okla State Med Assoc Date: 2018-10